Skip to content Norwegian Medical Products Agency Norwegian Medical Products Agency

Pricing of medicines



Norway has a statutory pricing policy for prescription-only medicines (POM) with MA for human use. The  policy is currently put into practice by the maximum price regulation and the stepped-price (“trinnpris”)  regulation.

The maximum price regulation at pharmacy purchase price (PPP) level, regulated in the Norwegian Act on Medicinal Products, was implemented in 2002. Before entering the Norwegian market, the Marketing Authorisation Holder (MAH) must apply for a maximum price with the Norwegian Medical Products Agency 

The Stepped price model (Trinnprismodellen) with generic competition was introduced in 2005 to reduce costs incurred by the National Insurance Scheme (NIS) and patients in relation to the use of generic  medicines. Since august 2021 there has also been a stepped price model for biosimilars.

In the stepped price models – for generic or biosimilar medicines, the price of a pharmaceutical product is reduced stepwise through predefined rates. This occurs after the pharmaceutical product has lost patent protection and hence is exposed to generic or biosimilar competition. The Stepped price model for generic medicines has been modified four times after its introduction with the aim of reducing medicine prices. 

Contact us

Unit for price regulation and market analysis

22 89 77 00